World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

IntelliGenome Appoints SIMED as Exclusive Distributor for CRISPR-TB™ in Peru and Ecuador

Cision PR Newswire by Cision PR Newswire
September 8, 2026
in Press Releases - Lifestyle
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

HOUSTON and QUITO, Ecuador, Sept. 8, 2026 /PRNewswire/ — IntelliGenome, Inc. today announced the appointment of SIMED S.A. as its exclusive distributor for the CRISPR-TB™ Blood Test in Peru and Ecuador.

IntelliGenome received DIGEMID registration approval for the CRISPR-TB Blood Test in Peru, enabling commercial distribution in one of the region’s most important tuberculosis markets. Under the new partnership, SIMED will initiate the product registration process in Ecuador.

CRISPR-TB is an innovative molecular blood test that detects circulating Mycobacterium tuberculosis cell-free DNA, representing a novel non-sputum approach to tuberculosis detection.

SIMED was selected for its strong expertise in tuberculosis diagnostics, molecular laboratory solutions, and established relationships with hospitals, reference laboratories, and public health institutions throughout Peru and Ecuador.

“SIMED combines deep tuberculosis expertise with one of the region’s strongest molecular diagnostics organizations, making them an ideal partner to accelerate adoption of CRISPR-TB across Peru and Ecuador,” said Kurt Wehrle, Vice President, Partnerships & Strategic Alliances at IntelliGenome.

The partnership significantly expands IntelliGenome’s commercial presence in Latin America while strengthening SIMED’s tuberculosis diagnostics portfolio with an innovative blood-based molecular technology.

“CRISPR-TB is an important addition to our tuberculosis diagnostics portfolio and reinforces our commitment to bringing innovative molecular technologies to laboratories throughout Peru and Ecuador.” said Abelardo Cruces, General Laboratory and Biosciences Business Manager at SIMED.

About IntelliGenome

IntelliGenome, Inc. is a molecular diagnostics company focused on the development and commercialization of innovative CRISPR-based diagnostic technologies. The company’s CRISPR-TB™ platform utilizes proprietary molecular detection technologies to identify tuberculosis from blood samples and is being evaluated globally through collaborations with clinical, academic, and public health partners. IntelliGenome is advancing both laboratory-based and near-patient testing solutions to expand access to tuberculosis diagnostics worldwide.

About SIMED

Founded in 1985, SIMED S.A. is one of the leading providers of diagnostic, laboratory, and life science solutions in Peru and Ecuador. Through long-standing partnerships with many of the world’s leading healthcare companies, SIMED supports hospitals, public health institutions, clinical laboratories, and research organizations with advanced technologies and specialized technical expertise.

Media Contact:
Kurt Wehrle
Vice President, Partnerships & Strategic Alliances
IntelliGenome, Inc.
422138@email4pr.com 
Mobile: (847)542-1542

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/intelligenome-appoints-simed-as-exclusive-distributor-for-crispr-tb-in-peru-and-ecuador-302872329.html

SOURCE IntelliGenome

Cision PR Newswire

Cision PR Newswire

Related Posts

NIQ Research Reveals How Time, Trust and Support Are Reshaping the U.S. Mother and Baby Market

September 8, 2026

BRAD PITT HEADED TO BRISTOL MOTOR SPEEDWAY FOR BASS PRO SHOPS NIGHT RACE

September 8, 2026

GS1 Connect 2027 Call for Presentations Now Open

September 8, 2026

egnite Unveils Major CardioCare® Platform Improvements with a New UI that Enables Even Faster and Easier Access to Critical CV Data

September 8, 2026

AiDAP end-to-end agentic execution for enterprise migration and modernization.

September 8, 2026

Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

September 8, 2026

Popular News

  • NIQ Research Reveals How Time, Trust and Support Are Reshaping the U.S. Mother and Baby Market

    0 shares
    Share 0 Tweet 0
  • oneworld Loyalty Summit Brings Together Experts to Explore Latest Trends and Innovations Shaping the Loyalty Landscape

    0 shares
    Share 0 Tweet 0
  • Monterey Bay Aquarium’s Ocean in Motion / La Danza del Mar opens November 7, 2026

    0 shares
    Share 0 Tweet 0
  • Business-Class.com Partners with beOnd to Offer Premium Leisure Travelers All-Lie-Flat Flying to the Maldives and Red Sea

    0 shares
    Share 0 Tweet 0
  • Chili’s® Announces Historic $150 Million Commitment to St. Jude Children’s Research Hospital®, Fueled by Guests and Team Members

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler